A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Anticoagulant reversal for life-threatening bleeds Initial IV bolus: 800 mg IV target infusion rate of 30 mg/min Follow-on IV infusion: 8 mg/min IV for up to 120 min Dose based on rivaroxaban or apixaban dose.FDA approved in May 2018, limited availability June 2018 with broader commercial launch in early 2019.Inhibits the activity of the Tissue Factor Pathway Inhibitor (TFPI), increasing tissue factor-initiated thrombin generation.

Binds and sequesters factor Xa inhibitors There are 2 dosage regimens (low dose or high dose) to choose from Safety and efficacy of an additional dose has not been established Low or high dose regimens Low dose Initial IV.Dosage Forms: solution reconstituted, 100 mg per vialĪdult Dosing Determined by last dose, type of factor Xa inhibitor, and dose of inhibitorĤ00 mg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by 4 mg/minute for up to 120 minutesĨ00 mg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by 8 mg/minute for up to 120 minutes Start the bolus at a target rate of approximately 30 mg/min Within 2 minutes following the bolus dose, administer the continuous IV infusion for up to 120.Type: factor Xa inhibitor reversal, antidote.2.1 Determined by last dose, type of factor Xa inhibitor, and dose of inhibitor High dose: 800 mg IV bolus administered at a rate of 30 mg/minute, followed within 2 minutes by an IV infusion of 8 mg/minute for up to 120 minutes.

Andexanet alfa dosing